...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Trial

That was my point.Bear posted that the results of the trial should be coming soon.The fact that 44of 58 patients in the trial are Invited to remain on the combo would seem to indicate a degree of success or am I dreaming in technicolour 

Share
New Message
Please login to post a reply